ARCHIVES

Ovarian Suppression Treatment Plus Tamoxifen Can Lower Recurrence Risk

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

News Analysis: Generic Drug Industry’s Efforts to Eliminate Shortages Raises Antitrust Law Questions

April 27, 2012

NCI Grant Boosts UCLA Bladder Cancer Project

October 25, 2002

Howard Hughes Medical Institute Seeks up to 25 New Researchers

January 17, 2014

Panel Resumes Deliberations

January 4, 1980

Clinical trials: ORI Cites Data Manager For Misconduct; Results Not Affects, NCI Says

April 2, 1999

Adcetris Granted Approval For Hodgkin’s Lymphoma and ALCL

September 30, 2011